Kim, Young Jin, Krainer, Adrian R (January 2023) Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives. Molecules and Cells, 46 (1). pp. 10-20. ISSN 1016-8478
![[thumbnail of 2023-Krainer-Antisense-oligonucleotide-therapeutics-for-cystic-fibrosis-recent-developments-and-perspectives.pdf]](https://repository.cshl.edu/style/images/fileicons/application_pdf.png) |
PDF
2023-Krainer-Antisense-oligonucleotide-therapeutics-for-cystic-fibrosis-recent-developments-and-perspectives.pdf Available under License Creative Commons Attribution Non-commercial Share Alike. Download (5MB) |
Abstract
Antisense oligonucleotide (ASO) technology has become an attractive therapeutic modality for various diseases, including Mendelian disorders. ASOs can modulate the expression of a target gene by promoting mRNA degradation or changing pre-mRNA splicing, nonsense-mediated mRNA decay, or translation. Advances in medicinal chemistry and a deeper understanding of post-transcriptional mechanisms have led to the approval of several ASO drugs for diseases that had long lacked therapeutic options. For instance, an ASO drug called nusinersen became the first approved drug for spinal muscular atrophy, improving survival and the overall disease course. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF). Although Trikafta and other CFTR-modulation therapies benefit most CF patients, there is a significant unmet therapeutic need for a subset of CF patients. In this review, we introduce ASO therapies and their mechanisms of action, describe the opportunities and challenges for ASO therapeutics for CF, and discuss the current state and prospects of ASO therapies for CF.
Actions (login required)
 |
Administrator's edit/view item |